Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19666
Title: Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
Authors: Hong, Thai P;Gow, Paul J;Fink, Michael;Dev, Anouk;Roberts, Stuart K;Nicoll, Amanda;Lubel, John S;Kronborg, Ian;Arachchi, Niranjan;Ryan, Marno;Kemp, William W;Knight, Virginia;Sundararajan, Vijaya;Desmond, Paul;Thompson, Alexander Jv;Bell, Sally J
Affiliation: St Vincent's Hospital Melbourne, Melbourne, VIC
Austin Health, Heidelberg, Victoria, Australia
Monash Health, Melbourne, VIC
Eastern Health, Melbourne, VIC
Western Health, Melbourne, VIC
Alfred Hospital, Melbourne, VIC
University of Melbourne, Melbourne, VIC
Issue Date: 15-Oct-2018
Citation: The Medical journal of Australia 2018; 209(8): 348-354
Abstract: To determine the factors associated with survival of patients with hepatocellular carcinoma (HCC) and the effect of HCC surveillance on survival. Prospective population-based cohort study of patients newly diagnosed with HCC in seven tertiary hospitals in Melbourne, 1 July 2012 - 30 June 2013. Overall survival (maximum follow-up, 24 months); factors associated with HCC surveillance participation and survival. 272 people were diagnosed with incident HCC during the study period; the most common risk factors were hepatitis C virus infection (41%), alcohol-related liver disease (39%), and hepatitis B virus infection (22%). Only 40% of patients participated in HCC surveillance at the time of diagnosis; participation was significantly higher among patients with smaller median tumour size (participants, 2.8 cm; non-participants, 6.0 cm; P < 0.001) and earlier Barcelona Clinic Liver Cancer (BCLC) stage disease (A/B, 59%; C/D, 25%; P < 0.001). Participation was higher among patients with compensated cirrhosis or hepatitis C infections; it was lower among those with alcohol-related liver disease or decompensated liver disease. Median overall survival time was 20.8 months; mean survival time was 18.1 months (95% CI, 16.6-19.6 months). Participation in HCC surveillance was associated with significantly lower mortality (adjusted hazard ratio [aHR], 0.60; 95% CI, 0.38-0.93; P = 0.021), as were curative therapies (aHR, 0.33; 95% CI, 0.19-0.58). Conversely, higher Child-Pugh class, alpha-fetoprotein levels over 400 kU/L, and later BCLC disease stages were each associated with higher mortality. Survival for patients with HCC is poor, but may be improved by surveillance, associated with the identification of earlier stage tumours, enabling curative therapies to be initiated.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19666
PubMed URL: 30309301
Type: Journal Article
Subjects: Hepatitis B
Hepatitis C
Liver cirrhosis
Liver diseases, alcoholic
Liver neoplasms
Neoplasms, epidemiology
Preventive medicine
Survival analysis
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.